AbbVie Inc. reported results for the 2026 quarter with revenue of $16.99B and diluted EPS of $2.03, driven by strong growth in key brands and a rebound in net earnings versus the prior-year period.Financial Highlights¹ Reported as “Net revenues”. ² Reported as “Net earnings attributable to AbbVie I…
As per a media report over the weekend, AstraZeneca Plc (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) are in potential discussions to form a pharmaceutical giant valued at nearly $400 billion.The news took the healthcare sector by storm, and the merger would position AstraZeneca as the world’s…
Amazon.com Inc. (NASDAQ:AMZN)‘s best earnings-day pop in years and a nearly $475 billion wipeout in Apple Inc. (NASDAQ:AAPL) market valuation pulled Wall Street in opposite directions Friday, leaving indexes searching for direction into midday as the AI trade split in two.The S&P 500 held a 0.5% ga…
Moleculin Biotech Inc. (NASDAQ:MBRX) released updated blinded preliminary outcomes from Part A of its Phase 2/3 MIRACLE trial evaluating Annamycin with cytarabine for relapsed or refractory acute myeloid leukemia.Concurrently, the biopharmaceutical enterprise announced the pricing of a public stock…
Second quarter results exceeded expectations with double-digit revenue growth and raised full-year guidance. Immunology and neuroscience segments drove performance, while the Apogee acquisition and new product approvals strengthen the long-term outlook.Based on AbbVie Inc. [ABBV] Q2 2026 Audio Tran…
AbbVie NYSE:ABBV fell 3.46% premarket after trimming full-year guidance alongside second-quarter results that beat on both lines. Net revenues rose 10.2% to $16.99 billion against the $16.78 billion analysts expected, and adjusted diluted earnings of $3.65 a share topped the $3.60 consensus, up 22…
AbbVie (ABBV) heads into Q2 earnings with analysts forecasting revenue up 8.8% year‑over‑year, accelerating from last year’s 6.6% rise — a key metric for traders monitoring top‑lin
Pharmaceutical company AbbVie NYSE:ABBV will be announcing earnings results this Friday before market hours. Here’s what to look for.AbbVie beat analysts’ revenue expectations last quarter, reporting revenues of $15 billion, up 12.4% year on year. It was a mixed quarter for the company, with a miss…
Shares of Sellas Life Sciences (SLS) are sliding toward their worst month in over two years, but retail bulls are still buying weakness and holding out for a potential buyout as the company nears a key acute myeloid leukemia (AML) readout.SLS stock SLS stock has fallen 31% so far in July after exte…
Shares of Sellas Life Sciences (SLS) jumped 3% overnight late Monday as retail traders bet that the final acute myeloid leukemia (AML) readout could turn this week’s Fox appearance into a launchpad for Big Pharma interest.SLS stock surged 12% on Friday to close at $13.19, capping a 3% weekly gain.S…
AbbVie ABBV is scheduled to report second-quarter 2026 results on July 31, before the opening bell. While investor focus will primarily remain on the continued strength of the company’s blockbuster immunology franchise, the performance of its neuroscience portfolio is also expected to be closely wa…
WSW, NY, July 9th, 2026, FinanceWireIn June, Nuvectis Pharma NASDAQ:NVCT signed a deal that took it from a single-drug oncology company to the owner of one of the more closely watched assets in rare-disease medicine: NXP100, a once-a-day pill for a blood disorder called paroxysmal nocturnal hemoglo…
AbbVie ABBV announced that the European Commission (EC) approved the expanded use of Tepkinly (epcoritamab) for the relapsed or refractory follicular lymphoma (R/R FL) indication. The EC approved the drug in combination with rituximab and lenalidomide (Tepkinly+R2) for adult patients with R/R FL af…
AbbVie (NYSE:ABBV) reported a Phase 3 win as epcoritamab+lenalidomide met EPCORE DLBCL‑14's primary endpoint with strong PFS HRs (0.40 U.S., 0.44 ex‑U.S.) and expected safety, while the company paid Nxera $10M, lifting 2022 neuro R&D milestones to $40M amid up to $1.2B more possible.Previous Week R…
